Navigation Links
Medpace Strengthens Presence in Central Europe
Date:8/21/2007

CINCINNATI and PRAGUE, Czech Republic, Aug. 21 /PRNewswire/ -- Medpace, Inc., a leading global full-service contract research organization, today announced it has completed the acquisition of Monax s.r.o., a regional contract research organization (CRO) headquartered in Prague, Czech Republic. This move strengthens the Medpace presence in Central Europe and expands its capacity to provide full service clinical research management within the Czech Republic and Slovakia. Petr Potuznik, MD, the founder of Monax, will continue to lead Medpace clinical operations for the region.

"We are excited to welcome the Monax team to the Medpace family," said August Troendle, MD, Medpace Chief Executive Officer. "The expertise of Dr. Petr Potuznik and his highly trained team fit perfectly within our strategic global expansion plan."

"We have worked closely with Medpace in the past and found that our companies shared a high level of expertise and commitment to quality," said Potuznik. "Becoming part of the Medpace group allows the Monax team to grow and expand our presence and capabilities throughout the region."

About Medpace

Medpace is a global, research-based drug development company led by top therapeutic and regulatory experts who are driven to further the advancement of pharmaceutical agents for use in cardiology, metabolism, and oncology. Medpace has assembled the industry's most experienced and therapeutically focused team to execute at every level of the company's operations, providing complete and seamless drug development services.

Through specialized regulatory expertise and therapeutically focused clinical operations, Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development - from program planning and execution to product approval.

With more than 500 employees and clinical trial experience in nearly 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide within the core therapeutic areas of cardiology, metabolism, and oncology.

The Medpace group of companies also includes

Imagepace - a centralized imaging laboratory with expertise in cIMT

Medpace Reference Laboratory - a centralized lab with therapeutically specialized testing

Medpace Clinical Pharmacology - a Phase I/IIa unit scheduled to open in Q1, 2008.

Contact: Stephanie Lusk 513-579-9911 x1102


'/>"/>
SOURCE Medpace, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. BIO 2007: Wisconsin makes its presence felt
2. TDS trades markets to gain Duluth presence
3. West Coast VC Establishes Midwest Presence in Madison
4. Sony Bets Heavy on Wisconsin Digital Entertainment Presence
5. Madison start-up Central Signal gets $350K grant
6. Will wireless Internet bypass the central city?
7. Norlight to expand fiber network into central Illinois
8. Centralization mania takes over
9. Meterologix Media Division acquired by Madison-based Weather Central
10. Weather Central launches second satellite
11. Development of an NK2 neuropeptide receptor binding assay using LEADseeker Multimodality Imaging System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... Oct. 9, 2017  BioTech Holdings announced today ... which its ProCell stem cell therapy prevents limb ... The Company, demonstrated that treatment with ProCell resulted ... saved as compared to standard bone marrow stem ... resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board meeting in North Carolina, ... Harvard University’s Departments of Physics and Astronomy, has been selected for membership in ... team for the 2015 Breakthrough Prize in Fundamental physics for the discovery of the ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... the medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses the surface ... detecting generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The prospective multicenter ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... genomic technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first ... accompanying cloud-based bioinformatics software to perform Hi-C metagenome deconvolution using their own ...
Breaking Biology Technology:
(Date:4/6/2017)... April 6, 2017 Forecasts by ... Document Readers, by End-Use (Transportation & Logistics, Government & ... Gas & Fossil Generation Facility, Nuclear Power), Industrial, Retail, ... Are you looking for a definitive report ... ...
(Date:4/4/2017)... April 4, 2017   EyeLock LLC , a ... the United States Patent and Trademark Office (USPTO) has ... the linking of an iris image with a face ... represents the company,s 45 th issued patent. ... very timely given the multi-modal biometric capabilities that have ...
(Date:3/30/2017)... 30, 2017 Trends, opportunities and forecast in ... by technology (fingerprint, AFIS, iris recognition, facial recognition, hand ... by end use industry (government and law enforcement, commercial ... banking, and others), and by region ( North ... Asia Pacific , and the Rest of ...
Breaking Biology News(10 mins):